New Cancer Treatment Approved
FDA Approves Ziihera Regimens for First-Line HER2-Positive Gastroesophageal Cancer Treatment
Anonymous
Key Points
1
Ziihera (zanidatamab-hrii) is a bispecific antibody designed to bind HER2 at two extracellular domains (2 and 4), a dual-targeting approach that differentiates it from standard monoclonal HER2 therapies.
2
The HERIZON-GEA-01 trial enrolled 914 patients across roughly 300 trial sites in more than 30 countries, evaluating Ziihera-containing regimens as first-line therapy for HER2-positive gastroesophageal cancer.
3
Safety data from the trial indicated no new safety signals and that the adverse event profile aligned with the known safety profiles of Ziihera, Tevimbra, and chemotherapy.
4
Jazz’s FDA approvals trigger milestone payments: a $250 million upfront milestone to Zymeworks, with potential for up to $1.3 billion more in milestones and tiered royalties up to 20% of net sales; BeOne’s Asia Pacific collaboration could add up to $144 million in milestones with royalties up to 19.5% on net sales.
The FDA has approved Healio Ziihera (zanidatamab-hrii) in two new drug combinations to treat advanced gastroesophageal cancer. The approvals cover Ziihera with the immunotherapy Tevimbra plus chemotherapy, and Ziihera with chemotherapy alone — both for first-line treatment of HER2-positive tumors. The decision is based on WebMD trial data showing the combinations reduced disease progression or death by about one-third and extended survival to 26.4 months versus 19.2 months with standard therapy.
Ziihera is a bispecific antibody that binds to two different spots on the HER2 protein, a dual-targeting design that sets it apart from earlier HER2 therapies like trastuzumab. Since about 20% of gastroesophageal cancers are HER2-positive, these approvals could benefit tens of thousands of patients annually across the US and worldwide. Jazz Pharmaceuticals will receive up to $1.3 billion in future payments tied to the drug's sales performance.
Trial Results Show Major Survival Gains
The HERIZON-GEA-01 trial enrolled 914 patients across more than 30 countries to test Ziihera combinations as initial therapy. Healio reported that patients receiving Ziihera with Tevimbra plus chemotherapy had a median progression-free survival of 12.4 months, compared to 8.1 months for the standard treatment group. The survival advantage was even stronger in patients with PD-L1-negative tumors: 29.7 months versus 15.8 months with the control regimen.
Safety data from the trial showed no new warning signs. The side effect profile aligned with what doctors already know about Ziihera, Tevimbra, and chemotherapy individually. WebMD confirmed that the combinations were generally well-tolerated, clearing the way for FDA approval across both regimens and all PD-L1 patient statuses.
A New Front-Line Option Beyond Trastuzumab
For years, trastuzumab has been the standard HER2-targeting drug for advanced gastroesophageal cancer. Ziihera's unique design — binding HER2 at two extracellular domains instead of one — offers a mechanistically different approach that shows stronger clinical results. Jazz Pharmaceuticals emphasized that these approvals expand treatment options for patients who need more effective first-line therapies and potentially offer better outcomes in HER2-positive advanced disease.
Financial Milestones and Global Expansion Plans
The FDA approvals trigger substantial payments to Ziihera's developer, Zymeworks. Jazz Pharmaceuticals will pay $250 million upfront and up to $1.3 billion more in milestone payments tied to sales. Jazz will also pay tiered royalties of up to 20% on net sales. These approvals mark the second FDA clearance for zanidatamab in less than two years, reinforcing the Azymetric bispecific platform's clinical and commercial momentum.
Separately, BeOne Medicines — which holds Asia-Pacific collaboration rights — could earn up to $144 million in additional milestones and royalties reaching 19.5% of net sales in that region. This global partnership structure positions Ziihera for broad international adoption in a cancer type that affects hundreds of thousands of patients annually.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
11
Articles
35
Reach
46
A
AnonymousAuthor
